Last reviewed · How we verify
Mayne Glucagon — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Mayne Glucagon (Mayne Glucagon) — Hospira, now a wholly owned subsidiary of Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mayne Glucagon TARGET | Mayne Glucagon | Hospira, now a wholly owned subsidiary of Pfizer | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mayne Glucagon CI watch — RSS
- Mayne Glucagon CI watch — Atom
- Mayne Glucagon CI watch — JSON
- Mayne Glucagon alone — RSS
Cite this brief
Drug Landscape (2026). Mayne Glucagon — Competitive Intelligence Brief. https://druglandscape.com/ci/mayne-glucagon. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing